SEATTLE--(BUSINESS WIRE)--BEATBio, a Seattle, Wash.-based biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure, today announced the closing of a $2.5 million seed stage investment with funding provided by CET Capital Partners. Participating investors include the W Fund. The proceeds will be used to move BEATBio’s lead gene therapy product into clinical development.
